Belgium vs Netherlands: Access to anti-retroviral drugs, female
Belgium
89.0%
in 2023
Netherlands
89.0%
in 2023
Belgium rank
35th
Netherlands rank
35th
Access to anti-retroviral drugs, female over time
- Belgium
- Netherlands
How they compare
Belgium currently reports 89.0% against 89.0% in Netherlands, a difference of 0.0%.
The two have swapped places 2 times across 24 shared years of data; in 2000 it was Netherlands ahead.
Belgium ranks 35th and Netherlands ranks 35th of 141 countries.
Belgium has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belgium | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 63.3% | 62.9% | 0.4% | Belgium |
| 2010s | 87.0% | 77.7% | 9.3% | Belgium |
| 2020s | 88.0% | 86.8% | 1.2% | Belgium |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Belgium or Netherlands?
- Belgium, at 89.0% against 89.0% in Netherlands as of 2023.
- What is the difference in access to anti-retroviral drugs, female between Belgium and Netherlands?
- 0.0%, with Belgium ahead.
- How many years of comparable data are there for Belgium and Netherlands?
- 24 years are reported by both, from 2000 to 2023.
- How do Belgium and Netherlands rank globally for access to anti-retroviral drugs, female?
- Belgium ranks 35th and Netherlands ranks 35th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.